Emmaus Life Sciences Inc.

07/17/2024 | Press release | Distributed by Public on 07/17/2024 15:29

Management Change/Compensation Form 8 K

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

Appointment of Chief Executive Officer

On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.

Mr. Lee served as interim Co-President of the company since August 21, 2023 and as our Chief Operating Officer since July 2019. He has also served as a director and the Chairman of the Board since July 2019 and October 2, 2023, respectively. Mr. Lee's compensation as Chief Executive Officer will not change from his current compensation as described in "Item 11. Executive Compensation" beginning on page 51 of our Annual Report on Form 10-K, or Annual Report, filed with the Securities and Exchange Commission on July 3, 2024, which description is incorporated herein by reference.

George Sekulich, who served as interim Co-President along with Mr. Lee since October 2, 2023, will continue to serve as Chief Commercial Officer and Chief Information Officer, which offices he has held since August 2023 and July 2019, respectively. Prior to that time, he also served as Senior Vice President of Global Commercialization since July 2019.

For more information regarding Mr. Lee's and Mr. Sekulich's respective principal business experience, see "Item 10, Directors, Executive Officers and Corporate Governance" beginning on page 48 of our Annual Report, which information in incorporated herein by reference.

There are no family relationships between Mr. Lee and any of our other directors, executive officers, or persons nominated or chosen to become a director or executive officer. Mr. Lee is not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K.